Table 1.
Baseline Patient Characteristics Between Laparoscopic Anatomical Liver Resection (LAR) and Laparoscopic Non-Anatomical Liver Resection (LNAR) Groups Before and After Propensity Score Matching (PSM)
Characteristics | Before PSM | After PSM | ||||
---|---|---|---|---|---|---|
LAR (N=304) | LNAR (N=357) | P | LAR (N=250) | LNAR (N=250) | P | |
Age | 52.70±11.15 | 51.08±11.37 | 0.067 | 52.09±11.07 | 52.28±11.39 | 0.855 |
Gender | 0.082 | 0.797 | ||||
Male | 252 (82.9%) | 313 (87.7%) | 214 (85.6%) | 216 (86.4%) | ||
Female | 52 (17.1%) | 44 (12.3%) | 36 (14.4%) | 34 (13.6%) | ||
HBV | 259 (85.2%) | 309 (86.6%) | 0.617 | 218 (87.2%) | 212 (84.8%) | 0.439 |
HCV | 6 (2.0%) | 2 (0.6%) | 0.098 | 0 (0%) | 2 (0.8%) | 0.156 |
Liver cirrhosis | 196 (64.5%) | 238 (66.7%) | 0.554 | 167 (66.8%) | 162 (64.8%) | 0.637 |
Child-Pugh score | 1.000 | 1.000 | ||||
A | 304 (100%) | 357 (100%) | 250 (100%) | 250 (100%) | ||
B | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
ASA score | 0.650 | 0.471 | ||||
I | 168 (55.3%) | 191 (53.5%) | 143 (57.2%) | 135 (54.0%) | ||
II | 136 (44.7%) | 166 (46.5%) | 107 (42.8%) | 115 (46.0%) | ||
TBIL (µmol/L) | 15.70±6.02 | 16.16±6.14 | 0.331 | 15.52±6.12 | 15.99±6.16 | 0.389 |
ALT (IU/L) | 38.21±23.89 | 43.52±33.93 | 0.022* | 39.56±24.91 | 38.21±26.33 | 0.556 |
ALB | 42.15±4.06 | 42.68±3.97 | 0.093 | 42.45±3.96 | 42.43±3.98 | 0.952 |
PT (INR) | 1.01±0.06 | 1.02±0.08 | 0.119 | 1.01±0.06 | 1.01±0.07 | 0.756 |
Plt (×103/μL) | 150.27±69.52 | 130.11±54.46 | <0.001* | 138.68±55.73 | 140.20±58.47 | 0.767 |
ICG-R15 (%) | 4.68±2.94 | 5.24±3.06 | 0.017* | 4.75±2.94 | 4.68±2.73 | 0.777 |
AFP (≥400 ng/mL) | 78 (25.7%) | 99 (27.7%) | 0.549 | 66 (26.4%) | 63 (25.2%) | 0.759 |
Largest tumor diameter | 0.001* | 0.647 | ||||
≤ 5cm | 225 (74.0%) | 303 (84.9%) | 201 (80.4%) | 205 (82.0%) | ||
>5cm | 79 (26.0%) | 54 (15.1%) | 49 (19.6%) | 45 (18.0%) | ||
Tumor number | 0.016* | 0.112 | ||||
1 | 292 (96.1%) | 324 (90.8%) | 241 (96.4%) | 236 (94.4%) | ||
2–3 | 10 (3.3%) | 31 (8.7%) | 7 (2.8%) | 14 (5.6%) | ||
≥4 | 2 (0.7%) | 2 (0.6%) | 2 (0.8%) | 0 (0%) | ||
Range of LR | 0.078 | 0.455 | ||||
Minor | 245 (80.6%) | 306 (85.7%) | 215 (86.0%) | 209 (83.6%) | ||
Major | 59 (19.4%) | 51 (14.4%) | 35 (14.0%) | 41 (16.4%) | ||
Tumor Location | 0.024* | 0.845 | ||||
Central segments (1, 4a, 7, 8) | 80 (26.3%) | 123 (34.5%) | 73 (29.2%) | 75 (30.0%) | ||
Peripheral segments (2, 3, 4b, 5, 6) | 224 (73.7%) | 234 (65.5%) | 177 (70.8%) | 175 (70.0%) | ||
Resection tumor margin | 0.306 | 0.432 | ||||
≥1cm | 290 (95.4%) | 346 (96.9%) | 241 (96.4%) | 244 (97.6%) | ||
<1cm | 14 (4.6%) | 11 (3.1%) | 9 (3.6%) | 6 (2.4%) | ||
Margin status | 0.356 | 1.000 | ||||
Negative | 304 (100%) | 356 (99.7%) | 250 (100%) | 250 (100%) | ||
Positive | 0 (0%) | 1 (0.3%) | 0 (0%) | 0 (0%) | ||
Histological grade | 0.514 | 0.788 | ||||
Low | 41 (13.5%) | 39 (10.9%) | 33 (13.2%) | 30 (12.0%) | ||
Moderate | 238 (78.3%) | 292 (81.8%) | 197 (78.8%) | 203 (81.2%) | ||
High | 25 (8.2%) | 26 (7.3%) | 20 (8.0%) | 17 (6.8%) | ||
Satellite nodule | 0.064 | 1.000 | ||||
Positive | 0 (0%) | 4 (1.1%) | 0 (0%) | 0 (0%) | ||
Negative | 304 (100%) | 353 (98.9%) | 250 (100%) | 250 (100%) | ||
TNM stage | 0.041* | 0.476 | ||||
I–II | 301 (99.0%) | 345 (96.6%) | 247 (98.8%) | 245 (98.0%) | ||
III–IV | 3 (1.0%) | 12 (3.4%) | 3 (1.2%) | 5 (2.0%) |
Note: *, P < 0.05, statistical significance.
Abbreviations: HBV, Hepatitis B virus; HCV, Hepatitis C virus; ASA, American Society of Anesthesiologists; TBIL, Total bilirubin; ALT, Alanine transaminase; PT, Prothrombin time; Plt, Platelet; AFP, Alpha-fetoprotein; ICG-R15, Indocyanine green retention test at 15 minutes.